Navigation Links
Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
Date:5/12/2011

ng Statements Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans to develop and commercialize its product candidates, including the Neo-Urinary Conduit and the Neo-Kidney Augment; (ii) expectations regarding the initial clinical trial of the Neo-Urinary Conduit and (iii) expectations regarding planned preclinical studies of the Neo-Kidney Augment. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. For instance there can be no assurance that: (i) the Company's Neo-Urinary Conduit clinical trial will not be placed on clinical hold by the Food and Drug Administration, or FDA; (ii) patients enrolled in the Company's Neo-Urinary Conduit clinical trial will not experience additional adverse events, which could delay clinical trials or cause the Company to terminate the development of the Neo-Urinary Conduit; (iii) the Company will be able to successfully enroll patients in its clinical trials, including its initial clinical trial for the Neo-Urinary Conduit; (iv) the results of the clinical trial for the Neo-Urinary Conduit will support further development of that product candidate; (v) data from the Company's ongoing preclinical studies will continue to be supportive of advancing its preclinical product candidates; and (vi) the Company will be able to progress its product candidates that are undergoing preclinical testing, including the Neo-Kidney Augment, into clinical trial and (vii) the Company will be able to obtain the capital it needs to develop its product candidates and continue its operations.  For additional factors which could cause actual results to differ from expectations, reference is made to th
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
2. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
3. Tengion Announces Second Closing of Series C Financing
4. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
5. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
6. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
7. Tengion Appoints A. Brian Davis Chief Financial Officer
8. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
9. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
10. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
11. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... , ... August 27, 2015 , ... Inc. Magazine released ... ranking iLab Solutions as number 1,361 in growth for the three years through 2014. ... top 0.1% fastest-growing privately held organizations in the country. , “We are thrilled ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... Barr,Pharmaceuticals, Inc. (NYSE: BRL ) today announced that ... U.S. Food & Drug,Administration (FDA) to manufacture and market ... hydrobromide extended release,capsules), eq. to 8 mg, 16 mg ... the,first company to file an Abbreviated New Drug Application ...
... Receives $1.1 Million to Investigate Innocence Claims, ... (DOJ) today announced over $1.1 million to the ... reviewing cases where DNA testing and,evidence may prove ... Justice,Programs (OJP), the funding is one of five ...
... ProSource 2.0 is a customized lab supply ordering system ... of every lab supply they currently order. ProSource then ... prices to ensure savings on every order. ProSource eliminates ... lab in your company to order from the same ...
Cached Biology Technology:Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules 2Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules 3Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules 4Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules 5Department of Justice Provides States With Funding for Testing in Postconviction Cases 2ProSource 2.0 Offers Value, Savings for Lab Supplies 2
(Date:8/12/2015)... , August 12, 2015 As ... mobile payment innovation and advanced biometrics technology is accelerating ... way consumers rely on using their credit cards, the ... the future for payment services led by companies in ... ), :  Google, Inc. (NASDAQ: GOOG ), Apple ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s touch ... 2015 that relate to sales of FPC1155 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... manufacturer in China and we are proud ... for Z1 , its first ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... OAK RIDGE, Tenn., July 02, 2010 -- Using ... (DOE) Oak Ridge National Laboratory and the University of ... system that controls cellular motility, potentially giving researchers a ... both medical and biotechnology research. A new study ...
... Symposium held June 27, 28, and 29 in Leesburg, Virginia ... neurobiology from around the globe who are attempting to demystify ... half of in-depth sessions attended by nearly 150 investigators and ... The 2010 IRSF Symposium was Chaired by David ...
... mothers to breastfeed for at least the first six months ... problem can sabotage their efforts, University of Florida researchers say. ... connective tissue under the tongue is too tight. A tongue ... properly and painlessly, and this struggle can lead many new ...
Cached Biology News:Cell signaling classification system gives researchers new tool 2Cell signaling classification system gives researchers new tool 3Cell signaling classification system gives researchers new tool 4IRSF lauds record turn-out for annual Rett Syndrome Symposium 2Treating tongue tie could help more babies breastfeed 2Treating tongue tie could help more babies breastfeed 3
... 2b GenBank Accession Number ... peptide (C-QSQENQDTRPKVKAKK), corresponding to amino ... 2b Formulation: antiserum in 0.05% ... Quality Assurance: routinely evaluated by ...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Immunofixation Gel Kit, requires IF100 Reactivity: Human Applications: Immunofixation ...
...
Biology Products: